Shares of Piramal Pharma Limited edged lower on May 11, declining 1.37% or ₹2.47 to ₹177.38 on the NSE, as investors weighed a mixed set of quarterly results featuring strong revenue and operating profit growth against deteriorating capital efficiency metrics and rising leverage.
The stock traded in an intraday range of ₹176.04 to ₹179.52, against a previous close of ₹179.85. At current levels, Piramal Pharma is trading well below its 52-week high of ₹226 but above its 52-week low of ₹132.30, implying meaningful recovery from the lows even as the stock remains range-bound. Market capitalisation stands at approximately ₹23,502 crore. The stock currently carries no P/E ratio given its loss-making status at the net level, and offers a nominal dividend yield of 0.08%. Average daily volume is a substantial 65.8 lakh shares.
What did Piramal Pharma report for Q4 FY26?
Net sales for the quarter stood at ₹2,751.77 crore, reflecting 24.1% growth compared to the average of the preceding four quarters — a strong top-line print demonstrating sustained revenue momentum across the company’s contract development and manufacturing, complex hospital generics, and India consumer healthcare businesses.
The standout number was operating profit before interest, which reached ₹172.71 crore — a 611.1% jump relative to the previous four-quarter average. This sharp operational turnaround signals a significant shift in Piramal Pharma’s profitability trajectory, driven by operating leverage as revenues have scaled. The operating profit to interest coverage ratio peaked at 5.55 times for the quarter, reflecting meaningfully enhanced ability to service debt from operating cash flows — an important positive for a company that has carried significant leverage since its demerger from the erstwhile Piramal Enterprises.
What are the concerns?
Despite the strong operating numbers, two metrics stand out as caution flags. The return on capital employed for the half-year period registered at 2.61% — the lowest level in recent assessments — indicating that while the company is generating more operating profit in absolute terms, the efficiency with which it is deploying its capital base has moderated. For a company at Piramal Pharma’s scale, a sub-3% ROCE raises questions about long-term value creation from its invested capital.
Simultaneously, the debt-to-equity ratio rose to 0.70 times — the highest in the recent half-year span — suggesting incremental leverage has been added to fund operations or capital expenditure. A rising debt load alongside a low ROCE creates a risk dynamic where the cost of capital could exceed returns on deployed capital if not corrected over time.
The combination of a record-low ROCE and a multi-period-high debt-to-equity ratio likely explains why the stock is trading modestly lower despite the headline operating profit surge — the market is looking past the quarterly operating beat to the underlying capital efficiency question that remains unresolved.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult a registered financial advisor before making any investment decisions. Business Upturn does not hold any position in the securities mentioned.